NO20075113L - Proteinkinaseinhibitorer - Google Patents

Proteinkinaseinhibitorer

Info

Publication number
NO20075113L
NO20075113L NO20075113A NO20075113A NO20075113L NO 20075113 L NO20075113 L NO 20075113L NO 20075113 A NO20075113 A NO 20075113A NO 20075113 A NO20075113 A NO 20075113A NO 20075113 L NO20075113 L NO 20075113L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
useful
present
prodrugs
Prior art date
Application number
NO20075113A
Other languages
English (en)
Norwegian (no)
Inventor
David J Bearss
Hariprasad Vankayalapati
Cory L Grand
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of NO20075113L publication Critical patent/NO20075113L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20075113A 2005-04-28 2007-10-09 Proteinkinaseinhibitorer NO20075113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67646705P 2005-04-28 2005-04-28
PCT/US2006/016423 WO2006116733A2 (en) 2005-04-28 2006-04-28 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20075113L true NO20075113L (no) 2007-11-23

Family

ID=37029567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075113A NO20075113L (no) 2005-04-28 2007-10-09 Proteinkinaseinhibitorer

Country Status (13)

Country Link
US (1) US20090029982A1 (pt)
EP (1) EP1888588A2 (pt)
JP (1) JP2008539277A (pt)
KR (1) KR20080020602A (pt)
CN (1) CN101189239A (pt)
AU (1) AU2006239236A1 (pt)
BR (1) BRPI0609956A2 (pt)
CA (1) CA2604284A1 (pt)
IL (1) IL186744A0 (pt)
MX (1) MX2007013624A (pt)
NO (1) NO20075113L (pt)
WO (1) WO2006116733A2 (pt)
ZA (1) ZA200709269B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
CA2682733A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US8618097B2 (en) * 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US10699235B2 (en) * 2009-05-05 2020-06-30 Oracle America, Inc. System, method and computer readable medium for placing advertisements into web pages
PH12013501800A1 (en) 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
RS59002B1 (sr) 2012-01-27 2019-08-30 Univ Montreal Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
CN104804002B (zh) * 2015-04-08 2017-02-01 河南师范大学 一种9H‑嘧啶并[4,5‑b]吲哚类化合物的合成方法
US10828329B2 (en) 2015-06-05 2020-11-10 Hema-Quebec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
CN105037374B (zh) * 2015-07-14 2017-04-12 吉林大学 N‑丁基‑9H‑嘧啶并[4,5‑b]吲哚‑2‑甲酰胺的制备方法
CA3024273A1 (en) 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN112135618A (zh) 2018-02-20 2020-12-25 蒙特利尔大学 体内介导免疫应答的nk和dc细胞的扩增
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
MX2022007278A (es) * 2019-12-18 2022-09-19 Univ Montreal Moduladores del adaptador kbtbd4 de cullin 3 como compuestos anti-cáncer.
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239227C (en) * 1996-10-01 2007-10-30 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
SK3822002A3 (en) * 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
EP1964839A3 (en) * 2000-08-18 2008-11-05 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
CA2464934A1 (en) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.

Also Published As

Publication number Publication date
EP1888588A2 (en) 2008-02-20
MX2007013624A (es) 2008-02-12
US20090029982A1 (en) 2009-01-29
WO2006116733A3 (en) 2006-12-14
BRPI0609956A2 (pt) 2010-05-18
AU2006239236A1 (en) 2006-11-02
JP2008539277A (ja) 2008-11-13
ZA200709269B (en) 2009-01-28
WO2006116733A2 (en) 2006-11-02
CN101189239A (zh) 2008-05-28
KR20080020602A (ko) 2008-03-05
CA2604284A1 (en) 2006-11-02
IL186744A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20082496L (no) Pyrazinderivater
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
WO2009155121A3 (en) Inhibitors of pi3 kinase
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
MX2007013624A (es) Inhibidores de proteina cinasa.
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application